Kremlin says a Putin-Trump meeting is essential but needs advance preparation and must yield results
The Kremlin said on Friday (May 16, 2025) that a meeting between Russian President Vladimir Putin and U.S. President Donald Trump was essential but required considerable advance preparation and had to yield results when it happened.
Also Read | Trump downplays Putin's decision to skip Istanbul peace talks with Zelenskyy
Kremlin spokesman Dmitry Peskov was commenting after Mr. Trump said he would meet Mr. Putin "as soon as we can set it up".
"...Such a meeting is certainly necessary. It is necessary both primarily from the point of view of bilateral Russian-U.S. relations and from the point of view of having a serious conversation at the highest level about international affairs and on regional problems, including, of course, about the crisis over Ukraine," Mr. Peskov said.
Russian and Ukrainian negotiators were in Istanbul on Friday (May 15, 2025) for what was billed as their first direct peace talks in more than three years, under pressure from U.S. President Donald Trump to end Europe's deadliest conflict since World War Two.
Commenting on the Istanbul talks, Mr. Peskov said that the Russian negotiating team was in constant communication with Moscow and that President Putin was receiving real-time updates.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hans India
23 minutes ago
- Hans India
City leaders in Los Angeles call on Trump administration to stop increased immigration raids
California immigration news: The Los Angeles mayors united on June 11, 2025 to demand that the federal government stop the Trump administration crackdown growing immigration enforcement actions as these efforts have aroused fear in local communities and led to nationwide protests. President Donald Trump showed no indication he would respond to their requests. The commander overseeing operations disclosed that 500 National Guard members deployed during Los Angeles protests have received training to work with immigration agents. The Guard troops started these missions but it remains unclear if they will persist once protests cease. Maj Gen Scott Sherman expressed anticipation for increased activity while mentioning ongoing discussions about LA immigration protests. My attention remains centered on the events unfolding in Los Angeles right now. We are indeed very concerned about the situation. The demonstration at Los Angeles' civic center immediately before the second night curfew became chaotic when police in riot gear including horse-mounted officers charged into the crowd to push protesters out of City Hall Park using wooden batons. Police deployed crowd control projectiles which hit a young woman who lay on the ground writhing in pain due to bleeding from her hip. It wasn't clear what initiated the confrontation. Previously, protesters had ignited fireworks while heading toward the federal building which had been the location for multiple clashes during recent nights. As the confrontation heated up protesters showed their message with a lively dance party. Raymond Martinez described the entire protest as chill throughout with peaceful vibes. After passing the federal building horses appeared. Leaders from LA-area cities asked President Trump to discontinue the deployment of military forces alongside immigration policy USA personnel. Brenda Olmos, Paramount's vice mayor who sustained rubber bullet injuries during the weekend, demanded an end to the terrorization of our residents. "You need to stop these stepped-up ICE raids."
Time of India
26 minutes ago
- Time of India
Trump & Melania Face Boos In Dc: 'Les Misérables' Night At Kennedy Center Sparks Uproar
What was meant to be a classy evening at the Kennedy Center turned chaotic as President Donald Trump and First Lady Melania were met with a chorus of boos during their arrival at the Les Misérables performance. As the presidential couple made their entrance in full glam, the crowd's disapproval echoed through the venue. While MAGA supporters quickly tried to cover it up with loud 'USA' chants, the moment was already recorded and rapidly went viral across social media. Internet reactions exploded, critics hailed it as 'America booing back,' while Trump loyalists claimed the audio was manipulated or even AI-generated. The political divide was on full display, turning a cultural night into a digital battleground.
Mint
27 minutes ago
- Mint
Trump wants cheaper drugs like Europe has. How it works.
President Donald Trump doesn't just want to bring down prescription drug prices for Americans. He wants European countries to raise them to make up the revenue that drugmakers would lose from his policy. Trump is proposing a so-called most-favored-nation pricing model, which would set U.S. drug prices at the lowest level in other wealthy countries. But the pharmaceutical industry isn't buying into tying drug prices in the U.S. to prices in Europe—at least not knowing the details of the president's proposal. More details about the government's pricing model could come this week. On May 12, Trump directed government health officials to benchmark drug prices to international standards within 30 days. The lobbying group PhRMA, with members including U.S. pharma giants Eli Lilly, Pfizer, Johnson & Johnson, and AbbVie, has argued there are two reasons why U.S. drug prices are high: foreign countries not paying 'their fair share" for medicines, and middlemen such as pharmacy-benefit managers. Today, U.S. drug pricing is largely market driven. It involves negotiations between drug manufacturers, pharmacy-benefit managers, healthcare insurers and providers. European countries do it much differently. Each has its own way of determining drug prices, but most follow one of two broad approaches. The first approach, which Germany and France use, considers the overall clinical effectiveness of a new medicine. How does the new treatment compare to existing ones? Does it have added therapeutic benefits? If the new drug is substantially better, its price would reflect that. A second approach, used by the U.K., the Netherlands, and Sweden, analyzes cost effectiveness. This model not only compares the new drug to existing ones but also assesses the incremental value that the medicine brings to the health system. After the assessments, negotiations between drugmakers and the countries begin. Because many European countries have national health systems, they are in a strong negotiation position. If government negotiators think a medicine is too expensive for its effectiveness, they won't recommend its use. How Trump's MFN policy would work in practice isn't clear. Drug prices would probably be based on list prices in Europe since the prices paid by national health systems, or net prices, are confidential. The president's open-ended directive, laid out in an executive order, has many wondering how the U.S. could raise prices in Europe. Trump has made clear he wants to close the gap between U.S. and international prices, and has suggested he would use tariffs and export controls to achieve his goal. In theory, drugmakers could set list prices higher in Europe as long as it doesn't affect net prices, health policy expert Dr. Huseyin Naci told Barron's. In the U.K., for example, a higher list price could still lower the prices in other European countries. 'So that would still not be an acceptable approach to many other European countries," said Naci, who is associate professor of health policy at the London School of Economics. Overhauling Europe's decades-old pricing approaches would require fundamental changes to their pricing regulations—and there will be 'little appetite or ability" to alter them, Naci added. Cost is another complicating factor. 'Pharmaceutical spending is already one of the top categories of spending in many countries in terms of healthcare expenditure, so there's little room to accommodate higher prices and spending for pharmaceuticals in Europe," according to Naci. How Trump is planning to make Europeans pay more for drugs is the big question. He could use tariffs and trade negotiations as leverage. In early April, the president said a 'major" tax on pharmaceutical imports is coming 'very shortly," however nothing has been announced yet. In a trade agreement with the U.K. a month later, there is a provision on pharmaceuticals that states the U.K. will 'endeavor to improve the overall environment for pharmaceutical companies." What that means in practice still isn't clear. Write to Elsa Ohlen at
